Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kosuke Ohsawa has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification of a novel small-molecule compound that suppresses depolarization-induced CYP11B2 expression and aldosterone production in KCNJ5 mutant adrenocortical cells

    by Yuri Otsubo, Hiroki Shimada, Keita Hoshi, Ryo Ito, Thanh Phuong Nguyen, Hiroyuki Yamakoshi, Kosuke Ohsawa, Hirofumi Ueda, Hidetoshi Tokuyama, Yoshiro Saito, et al.

  • Open Access

    Total synthesis of the antifungal clinical candidate ASP2397 cyclohexapeptide facilitated by the chemo-selective reduction of secondary N -benzyloxyamides

    by Mohamed Osama Ibrahim Mohamed, Yutong Du, Kosuke Ohsawa, Atsushi Tahara, Yoshitaka Shimotai, Hiroshi Hamamoto, A Ganesan, Takayuki Doi

    ASP2397 is a siderophore-like cyclic hexapeptide with potent and rapid fungicidal activity against Aspergillus species. We report here its first total synthesis, enabled by an unprecedented one-pot chemoselective reduction of secondary N-benzyloxyamides that strictly preserves the fragile N–O bond. This transformation includes an Ir-catalyzed hydrosilylation with Et2SiH2, followed by NaBH3CN reduction of the resulting oxime derivatives in the presence of a carbamate protecting group and ester, providing efficient access to the non-canonical N-acetyl-N-hydroxyornithine (AhOrn) building block. The macrocycle was assembled via a solid-phase peptide synthesis (SPPS) and head-to-tail macrolactamization. A late-stage one-pot debenzylation/chelation protocol successfully furnished the Al3+-chelated ASP2397. The integrity of the synthesized macrocycle was unequivocally confirmed by its targeted antifungal activity, mirroring the natural product and providing the necessary chemical platform for future structure-activity relationship studies.

  • Open Access

    Characterization of the ketoreductase domain of pikromycin module 2

    by Eiji Okamura, Kosuke Ohsawa, Hidetoshi Ban, Yoshiyuki Sugiyama, Junko Hashimoto, Kei Kudo, Masahito Yoshida, Kazuo Shin-Ya, Haruo Ikeda, Shunji Takahashi, et al.

    Polyketides represent a diverse class of natural products that serve as major sources of medicinal compounds. Their biosynthesis is generally catalyzed by multimodular polyketide synthase comprising functional domains, such as a β-ketosynthase, an acyltransferase, and an acyl carrier protein. These domains mediate the elongation of polyketide chains via decarboxylative Claisen-like condensation. A reductive loop comprising β-ketoreductase (KR), dehydratase (DH), and enoyl reductase domains converts the β-keto group into a hydroxy group, alkene, and alkane, respectively. Particularly, the KR domains are pivotal in determining the stereochemical configurations of the hydroxy and methyl groups on the macrolide backbone and are classified into A1, A2, B1, B2, C types. In this study, we performed a reductive loop exchange using pikromycin PKS, PikAIII module 5 (PikAIII-M5) as a template. The PikAIIIM5 was derived from the pikromycin biosynthetic gene cluster of the pikromycin-producing Streptomyces sp. AM4900. Next, we constructed a chimeric enzyme by replacing the KR domain of PikAIII-M5 with a DH–KR di-domain derived from PikAI module 2 (PikAI-M2), followed by the artificial addition of a thioesterase domain derived from PikAVI module 6. Thereafter, we evaluated the enzymatic activity of the construct using various chemically synthesized N-acetylcysteamine substrate analogs. This demonstrated that the chimeric module enzyme catalyzed the formation of (2R, 3R, 4S)-3-hydroxy-2,4-dimethylheptanoic acid, indicating that the KR domain of PikAI-M2 is a B1-type. These findings offer insights into the unresolved classification of KR domains that do not strictly conform to the Caffrey motif.


  • Open Access

    Recent highlights of the total synthesis of cyclic peptide natural products

    by Takayuki Doi, Masaya Kumashiro, Kosuke Ohsawa

    This review described the total synthesis of naturally occurring cyclic peptides covering 2020 to 2022 paying particular attention to the construction of their unique structures via macrocyclization.


  • Open Access

    Stereo-divergent Synthesis of Nonproteinogenic Amino Acids and Synthetic Study for Biologically Active Cyclopeptides

    by Kosuke Ohsawa

    Naturally occurring cyclopeptides are potential middle-molecule drug candidates beyond Lipinski’s rule of five. This paper focuses on the structural determination and structure–activity relationship (SAR) study of two cyclopeptides: asperterrestide A and decatransin. The proposed asperterrestide A was synthesized by solution-phase peptide elongation, followed by macrolactamization. NMR analysis and molecular modeling studies revealed the stereochemistry at the two α-positions of amino acid residues as opposite to each other. This was further confirmed by the total synthesis of the revised asperterrestide A. SAR study of synthetic products revealed that the β-hydroxy group in the nonproteinogenic amino acid residue was not essential for its cytotoxicity. In addition, N-alkyl-enriched peptide fragments of decatransin were synthesized in solution-phase without diketopiperadine formation. The putative candidates of decatransin was synthesized by convergent peptide coupling, followed by macrocyclization under modified Mitsunobu conditions. The structure of the natural decatransin, including its absolute configuration, was determined through a comparison of spectral data and the cytotoxicity exhibited by the synthetic products.

  • Cyclic Tetrapeptide Natural Product Asperterrestide A: Total Synthesis and Structural Revision

    by Takayuki Doi, Kosuke Ohsawa, Yuichi Masuda

    We have studied for the total synthesis of asperterrestide A, which is a cyclic tetrapeptide natural product reported to be composed of D-alanine, anthranilic acid, (2R,3S)-3-hydroxy-N-methylphenylalanine, and D-isoleucine or D-allo-isoleucine. We initially performed the total synthesis of the reported structure of asperterrestide A via solid-phase peptide synthesis and macrocyclization in solution. However, the spectral data of the synthetic (9R,25R)-derivative did not match those of the natural product. Then, we considered the true structure should be the (9S,25S)-stereoisomer because all NOE correlations predicted from its three-dimensional structures obtained by theoretical calculations were consistent with those observed in the natural product. Thus, the (9S,25S)-stereoisomer was synthesized through solution-phase synthesis because N-acylation of a polymer-supported (2S,3S)-3-hydroxy-N-methylphenylalanine derivative resulted in low yield. The (9S,25S)-stereoisomer was successfully synthesized and was found to be identical to the natural product. Therefore, the stereochemical configuration of asperterrestide A was corrected from (9R,25R) to (9S,25S). We also tested whether the DFT calculation of carbon chemical shifts can discriminate stereoisomers of cyclic tetrapeptides. After conformational analysis of four possible stereoisomers of asperterrestide A, Boltzmann-weighted carbon chemical shifts based on DFT calculations using Spartan’20 revealed a DP4 accuracy of 96%, which is sufficient to determine the stereochemical configuration among the stereoisomers. In addition, three 9-deoxy derivatives were synthesized and the cell growth inhibitory activity of the five synthetic compounds against human cancer cells (U937, MOLT-4, and A549) was evaluated. The results showed that the (9S,25S)-stereoisomer is as potent as asperterrestide A, whereas the (9R,25R)-derivative is not. The (9S,25S)-3-deoxy analogs were found to be equipotent to the natural product although the activity of the (9S,25R)-deoxy analog was lost.

  • Open Access

    Photocatalyzed Oxidative Decarboxylation Forming Aminovinylcysteine Containing Peptides

    by Masaya Kumashiro, Kosuke Ohsawa, Takayuki Doi

    The formation of (2S,3S)-S-[(Z)-aminovinyl]-3-methyl-D-cysteine (AviMeCys) substructures was developed based on the photocatalyzed-oxidative decarboxylation of lanthionine-bearing peptides. The decarboxylative selenoetherification of the N-hydroxyphthalimide ester, generated in situ, proceeded under mild conditions at −40 °C in the presence of 1 mol% of eosin Y-Na2 as a photocatalyst and the Hantzsch ester. The following β-elimination of the corresponding N,Se-acetal was operated in a one-pot operation, led to AviMeCys substructures found in natural products in moderate to good yields. The sulfide-bridged motif, and also the carbamate-type protecting groups, such as Cbz, Teoc, Boc and Fmoc groups, were tolerant under the reaction conditions.


  • Total Synthesis and Structural Determination of Cyclodepsipeptide Decatransin

    by Kosuke Ohsawa, Sakiko Fukaya, Takayuki Doi

    The structure determination of the 30-membered cyclodepsipeptide decatransin was demonstrated on the basis of total synthesis. Both (R)- and (S)-2-hydroxy-5-methylhexanoic acid derivatives were prepared via the Evans asymmetric alkylation. N-Alkyl-enriched peptide fragments were synthesized by the Cbz strategy in the solution phase without formation of diketopiperazine and epimerization. The synthesis of putative candidates was achieved by convergent peptide coupling of three peptide fragments, followed by macrocyclization under the Mitsunobu conditions.


  • Open Access

    A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo

    by Shoji Kokubo, Shinobu Ohnuma, Megumi Murakami, Haruhisa Kikuchi, Shota Funayama, Hideyuki Suzuki, Taiki Kajiwara, Akihiro Yamamura, Hideaki Karasawa, Norihiko Sugisawa, et al.

    The ATP-binding cassette subfamily G member 2 (ABCG2) transporter is involved in the development of multidrug resistance in cancer patients. Many inhibitors of ABCG2 have been reported to enhance the chemosensitivity of cancer cells. However, none of these inhibitors are being used clinically. The aim of this study was to identify novel ABCG2 inhibitors by high-throughput screening of a chemical library. Among the 5812 compounds in the library, 23 compounds were selected in the first screening, using a fluorescent plate reader-based pheophorbide a (PhA) efflux assay. Thereafter, to validate these compounds, a flow cytometry-based PhA efflux assay was performed and 16 compounds were identified as potential inhibitors. A cytotoxic assay was then performed to assess the effect these 16 compounds had on ABCG2-mediated chemosensitivity. We found that the phenylfurocoumarin derivative (R)-9-(3,4-dimethoxyphenyl)-4-((3,3-dimethyloxiran-2-yl)methoxy)-7H-furo [3,2-g]chromen-7-one (PFC) significantly decreased the IC50 of SN-38 in HCT-116/BCRP colon cancer cells. In addition, PFC stimulated ABCG2-mediated ATP hydrolysis, suggesting that this compound interacts with the substrate-binding site of ABCG2. Furthermore, PFC reversed the resistance to irinotecan without causing toxicity in the ABCG2-overexpressing HCT-116/BCRP cell xenograft mouse model. In conclusion, PFC is a novel inhibitor of ABCG2 and has promise as a therapeutic to overcome ABCG2-mediated MDR, to improve the efficiency of cancer chemotherapy.


  • Gold-Catalyzed Amide/Carbamate-Linked N,O-Acetal Formation with Bulky Amides and Alcohols

    by Kosuke Ohsawa, Shota Ochiai, Junya Kubota, Takayuki Doi

    A gold-catalyzed N,O-acetal formation was established to construct an amide/carbamate-linked N,O-acetal substructure with bulky alcohols. The acyliminium cation species generated from o-alkynylbenzoic acid ester in the presence of a gold catalyst is highly reactive and underwent nucleophilic attack of various bulky alcohols and phenols at room temperature under neutral conditions, leading to the corresponding N,O-acetals in yields of 34–89% with good functional group tolerance.